Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jun;21(2):89-93.
doi: 10.3904/kjim.2006.21.2.89.

Effect of fenofibrate in combination with urate lowering agents in patients with gout

You-Hyun Lee  1 , Chan-Hee Lee, Jisoo Lee
Affiliations

Effect of fenofibrate in combination with urate lowering agents in patients with gout

You-Hyun Lee et al. Korean J Intern Med. 2006 Jun.

Abstract

Background: To assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout.

Methods: Fourteen male patients with chronic tophaceous or recurrent acute attacks of gout were evaluated in an open-label pilot study of the hypolipidemic agent, fenofibrate (Lipidil Supra 160 mg/d). Patients were stable on urate lowering agents (allopurinol or benzbromarone) for > or = three months without acute attack for the most recent one month before participating. All patients were being treated with established doses of urate lowering agents without modification throughout the study. Clinical and biochemical assessments including serum uric acid, creatinine, liver function test and fasting serum lipid were measured at (1) baseline (2) after two months of fenofibrate treatment and (3) two months after fenofibrate was withdrawn.

Results: Serum uric acid was lowered by 23% after two months of fenofibrate treatment (6.93 +/- 2.16 vs. 5.22 +/- 1.16 mg/dL; p = 0.016). Triglyceride levels were also reduced after fenofibrate treatment (p = 0.001). However, this effect was reversed after the withdrawal (p = 0.002) of the drug. Alkaline phosphatase was reduced after fenofibrate treatment (p = 0.006), but increased 21% after the withdrawal of the drug (p = 0.002). By contrast, serum levels of high density lipoprotein and creatinine were increased 9% (p = 0.018) and 12% (p = 0.006), respectively; however, both levels were significantly decreased to the baseline levels upon withdrawal of fenofibrate.

Conclusions: Fenofibrate can effectively reduce uric acid levels in addition to its known hypolipidemic effect. Fenofibrate may be used as a potential urate lowering agent in patients with gout, especially in those with coexisting hyperlipidemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect on (A) uric acid (B) triglyceride (C) alkaline phosphatase (ALP) with and without fenofibrate therapy
Figure 2
Figure 2
Effect on (A) high density cholesterol (B) creatinine with and without fenofibrate therapy
See this image and copyright information in PMC

References

    1. Ghei M, Mihailescu M, Levinson D. Pathogenesis of hyperuricemia: recent advances. Curr Rheumatol Rep. 2002;4:270–274. - PubMed
    1. Dai SM, Han XH, Zhao DB, Shi YQ, Liu Y, Meng JM. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study. J Rheumatol. 2003;30:2245–2251. - PubMed
    1. Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96) J Rheumatol. 2001;28:1640–1646. - PubMed
    1. Yoo B. Serum uric acid levels in Korean adult population and their correlates. J Korean Rheum Assoc. 1995;2:60–68.
    1. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403–2406. - PubMed

Publication types